Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Rides High After Torcetrapib Collapse: Is Everything Old New Again?

This article was originally published in RPM Report

Executive Summary

The end of torcetrapib was bad news for Pfizer, and could be a death knell for the entire CETP inhibitor class. But it also makes Abbott's acquisition of Kos look prescient. Wall Street is taking notice.
Advertisement

Related Content

Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Torcetrapib's Silver Lining
FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate
FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate
Reliant: The Expensive Opportunities in Primary Care
Reliant: The Expensive Opportunities in Primary Care
Torcetrapib: Biomarker for the Big Pharma Business Model

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel